The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series A - II | Alive

Total Raised


Last Raised

$40M | 9 mos ago

About Sermonix Pharmaceuticals

Sermonix Pharmaceuticals is a biotechnology company with a targeted focus towards bringing female-specific oncology products through proof of concept, preclinical, and clinical development with a clear regulatory pathway in place.

Sermonix Pharmaceuticals Headquarter Location

3000 East Main St Suite 218

Columbus, Ohio, 43209,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sermonix Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sermonix Pharmaceuticals is included in 3 Expert Collections, including Women's Health & Wellness.


Women's Health & Wellness

1,471 items

Startups focused on providing products and services catering to women's health and wellbeing.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Sermonix Pharmaceuticals Patents

Sermonix Pharmaceuticals has filed 2 patents.

The 3 most popular patent topics include:

  • Breast cancer survivors
  • Estranes
  • Hormonal antineoplastic drugs
patents chart

Application Date

Grant Date


Related Topics



Breast cancer survivors, Hormonal antineoplastic drugs, Prodrugs, Synthetic estrogens, Estranes


Application Date


Grant Date


Related Topics

Breast cancer survivors, Hormonal antineoplastic drugs, Prodrugs, Synthetic estrogens, Estranes



Latest Sermonix Pharmaceuticals News

VIDEO: Combination of lasofoxifene, abemaciclib appears promising in breast cancer

Jun 21, 2022

Disclosures: Moore reports institutional research fundings from AstraZeneca, Daiichi Sankyo, Roche and Sermonix Pharmaceuticals. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio CHICAGO — Halle Moore, MD, director of breast medical oncology in the department of hematology and oncology at Cleveland Clinic Taussig Cancer Institute, spoke with Healio about findings from the ELAINE 2 study. Results from the study, which assessed a combination of lasofoxifene and abemaciclib in pre- and postmenopausal patients who had ER-positive/HER2-negative metastatic breast cancer and an ESR1 mutation , were presented at ASCO Annual Meeting. “In this trial, in participants who had progression following prior endocrine therapies as well as... up to one line of prior chemotherapy, the combination appeared to be very well tolerated,” Moore said. “Side effects were largely related to the abemaciclib and included gastrointestinal toxicity and cytopenias.” She added that two instances of thrombosis occurred among patients included in the study. “Impressively, however, was the median progression-free survival of 13.9 months that was seen in this refractory metastatic breast cancer population with ESR1 mutations,” Moore said. “So, we were very impressed with the duration of response and the clinical benefit rate in about two-thirds of the patients, who did not have disease progression in the first 24 weeks.” Read more about

Sermonix Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sermonix Pharmaceuticals Rank

  • When was Sermonix Pharmaceuticals founded?

    Sermonix Pharmaceuticals was founded in 2014.

  • Where is Sermonix Pharmaceuticals's headquarters?

    Sermonix Pharmaceuticals's headquarters is located at 3000 East Main St, Columbus.

  • What is Sermonix Pharmaceuticals's latest funding round?

    Sermonix Pharmaceuticals's latest funding round is Series A - II.

  • How much did Sermonix Pharmaceuticals raise?

    Sermonix Pharmaceuticals raised a total of $72.77M.

  • Who are the investors of Sermonix Pharmaceuticals?

    Investors of Sermonix Pharmaceuticals include Xontogeny, Richard DeSchutter, Anthony Wild, Wild Family Office, Lodewijk de Vink and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.